RET and neoplasm: The identification of a RET, NTRK, ALK, or MEK fusion or a BRAFV600E point mutation enable the use of a molecularly targeted agent, while tumours without one of these canonical molecular alterations may be amenable to a multi-kinase inhibitor (MKI), although these agents are typically associated with more side-effects [89].